![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to focus on TCR therapy and work through process development, preclinical analysis, and first-in-human trials using Xcellbio’s AVATAR Foundry platform for solid tumors.
Lead Product(s): TCR-based Therapy
Therapeutic Area: Oncology Product Name: TCR-based Therapy
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: AmplifyBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 20, 2024
Details:
The collaboration aims to explore novel approaches to improving therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR™ incubator system for cell therapy research and development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ElevateBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2024
Details:
Through the collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). s. The projects included in the collaboration will use Xcellbio’s AVATAR incubator system to grow.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Labcorp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 19, 2022
Details:
Proceeds will support the company’s continued growth as a pioneer in built-to-purpose technology platforms for the development and manufacturing of cell and gene-based therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Casdin Capital
Deal Size: $27.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 19, 2022